Cargando…

Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study

BACKGROUND: Therapeutic drug monitoring (TDM) aims to minimize the clinical impact of posaconazole and voriconazole pharmacokinetic variability. However, its benefits on clinical outcomes are still being defined. Additionally, TDM data are limited for posaconazole IV and delayed-release tablet formu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Whitley M., Schoeppler, Kelly E., Jaeger, Jaclyn, Mueller, Scott W., MacLaren, Robert, Fish, Douglas N., Kiser, Tyree H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594434/ https://www.ncbi.nlm.nih.gov/pubmed/28893246 http://dx.doi.org/10.1186/s12941-017-0235-8

Ejemplares similares

Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center
por: Van Matre, Edward T., et al.
Publicado: (2019)

Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
por: Kiser, Tyree H, et al.
Publicado: (2015)

Levetiracetam Pharmacokinetics in a Patient with Intracranial Hemorrhage Undergoing Continuous Veno-Venous Hemofiltration
por: Van Matre, Edward T., et al.
Publicado: (2017)

Comparison of clinical pharmacology of voriconazole and posaconazole
por: Sienkiewicz, Beata M., et al.
Publicado: (2016)

Retrospective Comparison of Andexanet Alfa and 4-Factor Prothrombin Complex for Reversal of Factor Xa-Inhibitor Related Bleeding
por: Stevens, Victoria M., et al.
Publicado: (2021)

Therapeutic Hypothermia Following Cardiopulmonary Arrest: A Systematic Review and Meta-Analysis with Trial Sequential Analysis
por: Maclaren, Robert, et al.
Publicado: (2023)

Therapeutic Drug Monitoring of Posaconazole: an Update
por: Dekkers, Bart G. J., et al.
Publicado: (2016)

Coagulation Factor Xa (Recombinant), Inactivated-Zhzo (Andexanet Alfa) Hemostatic Outcomes and Thrombotic Event Incidence at an Academic Medical Center
por: Stevens, Victoria M., et al.
Publicado: (2019)

Divergent humoral responses to 23-valent pneumococcal polysaccharide vaccine in critically-ill burn and neurosurgical patients
por: Mueller, Scott W., et al.
Publicado: (2018)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

The Effect of Posaconazole, Itraconazole and Voriconazole in the Culture Medium on Aspergillus fumigatus Triazole Resistance
por: Mroczyńska, Martyna, et al.
Publicado: (2020)

Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients
por: Ju, Chunrong, et al.
Publicado: (2022)

Comparative study of posaconazole and voriconazole for primary antifungal prophylaxis in patients with pediatric acute leukemia
por: Tu, Songji, et al.
Publicado: (2023)

Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations
por: Märtson, Anne‐Grete, et al.
Publicado: (2019)

Dose Optimisation of Posaconazole and Therapeutic Drug Monitoring in Pediatric Patients
por: Jia, Mengmeng, et al.
Publicado: (2022)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

755. Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies
por: Almutairy, Reem F, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

Itraconazole, Voriconazole, and Posaconazole CLSI MIC Distributions for Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates
por: Buil, Jochem B., et al.
Publicado: (2018)

Pharmacokinetic and Exposure Response Analysis of the Double-Blind Randomized Study of Posaconazole and Voriconazole for Treatment of Invasive Aspergillosis
por: Maertens, Johan A., et al.
Publicado: (2023)

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events
por: Chu, Helen Y, et al.
Publicado: (2013)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

974. Real World Experience of Posaconazole Therapeutic Drug Monitoring in Oncology Patients: Clinical Implications of Hypoalbuminemia as a Predictor of Subtherapeutic Posaconazole Levels
por: Pasikhova, Yanina, et al.
Publicado: (2023)

Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation
por: Döring, M., et al.
Publicado: (2013)

Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation
por: Jansen, Jeffrey W, et al.
Publicado: (2017)

Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases
por: Shen, Kunlu, et al.
Publicado: (2022)

In vitro susceptibility to amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin of Aspergillus spp. isolated from patients with haematological malignancies in Tunisia
por: Gheith, Soukeina, et al.
Publicado: (2014)

Cost Analysis of the Use of Voriconazole, Posaconazole and Micafungin in the Primary Prophylaxis of Invasive Fungal Infections in Recipients of Allogeneic Hematopoietic Stem Cell Transplants
por: Grau, Santiago, et al.
Publicado: (2015)

203 Optimization of Posaconazole (PCZ) Dosing with Multi-disciplinary Therapeutic Monitoring (TDM) Protocol
por: Pettit, Natasha, et al.
Publicado: (2014)

1537. Multicenter Study with Therapeutic Drug Monitoring (TDM) of Voriconazole (VRCZ) in Japanese Patients
por: Ueda, Takashi, et al.
Publicado: (2019)

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring
por: Hamada, Yukihiro, et al.
Publicado: (2013)

Posaconazole for lobomycosis
por: Pasqualotto, Alessandro C., et al.
Publicado: (2021)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

204 Voriconazole Restriction in Addition to Therapeutic Drug Monitoring (TDM) Protocol Results in Optimized Dosing
por: Pettit, Natasha, et al.
Publicado: (2014)

Performance evaluation of enzyme immunoassay for voriconazole therapeutic drug monitoring with automated clinical chemistry analyzers
por: Jeon, Yongbum, et al.
Publicado: (2017)

Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment
por: Valle-T-Figueras, José María, et al.
Publicado: (2021)

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in children
por: Chen, Xiaomin, et al.
Publicado: (2022)

Therapeutic Effect of Intrastromal Voriconazole, Topical Voriconazole, and Topical Natamycin on Fusarium Keratitis in Rabbit
por: Nejabat, Mahmood, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5k8acql4gmfjob0s54eehbok5o